当前位置: X-MOL 学术Am. J. Gastroenterol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Mongersen and SMAD-7 Inhibition, Not a Lucky 7 for Patients With IBD
The American Journal of Gastroenterology ( IF 8.0 ) Pub Date : 2020-05-01 , DOI: 10.14309/ajg.0000000000000564
Meenakshi Bewtra 1, 2, 3 , Gary R Lichtenstein 1
Affiliation  

The phase II mongersen (GED-0301) trial produced unparalleled success rates in Crohn's disease and generated much hope for a crippling disease. Unfortunately, the subsequent phase III trial was terminated early because of a lack of efficacy. We discuss the differences in trial design that may have contributed to these disparate findings and how these findings may serve as a lesson in subsequent therapeutic trials in Crohn's disease.

中文翻译:

Mongersen 和 SMAD-7 抑制,对 IBD 患者来说不是幸运的 7

II 期 mongersen (GED-0301) 试验在克罗恩病中产生了无与伦比的成功率,并为一种致残的疾病带来了很大的希望。不幸的是,随后的 III 期试验因缺乏疗效而提前终止。我们讨论了可能导致这些不同发现的试验设计差异,以及这些发现如何作为后续克罗恩病治疗试验的经验教训。
更新日期:2020-05-01
down
wechat
bug